Literature DB >> 6717064

Natural killer (NK)-cell activity and antibody-dependent cellular cytotoxicity (ADCC) in primary preleukemic syndrome.

G Kerndrup, K Meyer, J Ellegaard, P Hokland.   

Abstract

In 13 patients with a multi-parameter based diagnosis of primary acquired preleukemic syndrome (PPS), natural killer (NK) cell activity and antibody-dependent cellular cytotoxicity (ADCC) were investigated on peripheral blood mononuclear cell (MNC) fractions. In all but two patients a defective NK activity was found. Lymphocyte-monocyte mixture experiments demonstrated that this was not due to suppressor monocytes. Furthermore, NK activity was defective when both myeloid and non-myeloid target cell lines were used. Addition of human leukocyte interferon to the NK cultures augmented the cytotoxicity, which exhibited the same kinetics as that of normal controls, but NK activity levels remained subnormal. These data strongly indicate that the decreased NK activity seen in the patients is due to a decreased number of circulating NK cells. In contrast ADCC was within the normal range both when MNC suspensions as well as when purified peripheral blood lymphocytes were used as effector cells thus ruling out subnormal lymphocyte ADCC masked by the presence of monocyte ADCC. These results demonstrate that PPS patients have a selective NK defect with an intact lymphocyte ADCC function. Whether this defect will prove to be valuable in the assessment of a malignant transformation in a given patient will await further longitudinal NK studies and clinical follow-up of the patients.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6717064     DOI: 10.1016/0145-2126(84)90147-4

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  14 in total

1.  Refractory anaemia terminating in a combined lymphoproliferative and myeloproliferative disorder.

Authors:  L Camba; M V Joyner
Journal:  J Clin Pathol       Date:  1985-03       Impact factor: 3.411

Review 2.  The myelodysplastic syndromes.

Authors:  D M Layton; G J Mufti
Journal:  Br Med J (Clin Res Ed)       Date:  1987-07-25

3.  CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets.

Authors:  Michelle K Gleason; Julie A Ross; Erica D Warlick; Troy C Lund; Michael R Verneris; Andres Wiernik; Stephen Spellman; Michael D Haagenson; Alexander J Lenvik; Mark R Litzow; Pearlie K Epling-Burnette; Bruce R Blazar; Louis M Weiner; Daniel J Weisdorf; Daniel A Vallera; Jeffrey S Miller
Journal:  Blood       Date:  2014-03-20       Impact factor: 22.113

4.  Myelodysplastic syndrome associated with relapsing polychondritis: unusual transformation from refractory anemia to chronic myelomonocytic leukemia.

Authors:  T Shirota; O Hayashi; H Uchida; N Tonozuka; N Sakai; H Itoh
Journal:  Ann Hematol       Date:  1993-07       Impact factor: 3.673

Review 5.  T cell receptor mimic antibodies for cancer therapy.

Authors:  Leonid Dubrovsky; Tao Dao; Ron S Gejman; Elliott J Brea; Aaron Y Chang; Claire Y Oh; Emily Casey; Dmitry Pankov; David A Scheinberg
Journal:  Oncoimmunology       Date:  2015-06-01       Impact factor: 8.110

6.  Analysis of bone marrow and peripheral blood immunoregulatory lymphocytes in patients with myelodysplastic syndrome.

Authors:  O Iwase; S Aizawa; Y Kuriyama; M Yaguchi; M Nakano; K Toyama
Journal:  Ann Hematol       Date:  1995-12       Impact factor: 3.673

Review 7.  Myelodysplastic syndromes: pathogenesis, functional abnormalities, and clinical implications.

Authors:  A Jacobs
Journal:  J Clin Pathol       Date:  1985-11       Impact factor: 3.411

8.  Induction of soluble IL-2 receptor in patients with myelodysplastic syndromes undergoing high-dose interleukin-3 treatment.

Authors:  G Seipelt; A Ganser; H Duranceyk; A Maurer; O G Ottmann; D Hoelzer
Journal:  Ann Hematol       Date:  1994-04       Impact factor: 3.673

9.  Reduced natural killer (NK) function associated with high-risk myelodysplastic syndrome (MDS) and reduced expression of activating NK receptors.

Authors:  Pearlie K Epling-Burnette; Fanqi Bai; Jeffrey S Painter; Dana E Rollison; Helmut R Salih; Matthias Krusch; Jianxiang Zou; Edna Ku; Bin Zhong; David Boulware; Lynn Moscinski; Sheng Wei; Julie Y Djeu; Alan F List
Journal:  Blood       Date:  2007-03-06       Impact factor: 22.113

10.  The effect of recombinant alpha-interferon on natural killer cell activity and clinical course in patients with myelodysplastic syndrome.

Authors:  X Yataganas; G Eliopoulos; S Koulocheri; N Viniou; E Plata; P Panagiotidis; G Vayopoulos; J Meletis; P Fessas
Journal:  Ann Hematol       Date:  1991-06       Impact factor: 3.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.